NeoGenomics selects Aurora as primary partner for molecular testing

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has been selected by Aurora Diagnostics to be its primary partner for molecular testing at each of Aurora's 19 specialized anatomic pathology laboratories in the United States. 

As a result of this alliance, Aurora will be able to standardize advanced oncology-focused molecular testing services to support the needs of their referring physicians.  NeoGenomics gains the opportunity to provide its molecular and genetic oncology test offerings through Aurora Diagnostics' extensive network of Physicians to help deliver the highest level of patient care.

Bruce Walton, Executive Vice President of Aurora, stated, "Aurora's Molecular Medical Advisory Committee unanimously decided to partner with NeoGenomics after carefully considering a number of high-quality diagnostic laboratories.  Our committee evaluated quality-of-testing, breadth and depth of services, information technology capabilities, managed care access, product development pipeline, and future partnership opportunities.   We are thrilled to have selected NeoGenomics to provide Aurora's 110 licensed physicians with access to NeoGenomics fully integrated anatomic pathology and histology services."

Douglas VanOort, NeoGenomics Chairman and CEO, stated, "Aurora Diagnostics is one of the largest Anatomic Pathology organizations in America with a very strong reputation for quality.  Having served several of Aurora's regional laboratories in the past, we are now particularly pleased to enter into this broader alliance.  We believe our oncology-focused genetic and molecular testing services are a perfect complement to Aurora's extensive laboratory services, and we look forward to combining our capabilities for the benefit of Aurora's clients and their patients across America.